Oncogenic pathways associated with immunosuppression were significantly enriched in the low SLC7A5 group of the IMvigor210 cohort such as Wnt-β-catenin network, PPARG network, and IDH1, while EGFR-targeted therapy and radiotherapy were more beneficial for BLCA patients with high SLC7A5. Here, IDH1 is linked to bladder transitional cell carcinoma.